Event Details
Our final Mini-Networking Night of the year features Pharma/Biotech professionals from Novo Nordisk, Allarta Life Science, HDAX Therapeutics, CCRM, and Eikon Therapeutics on Wednesday, April 13, 2022. Interested in learning about careers in this exciting field? Register below!
Location
The event will be held virtually through Zoom. The Zoom link will be provided to registrants at a closer date.
Event Program
6:00 PM - 6:15 PM Guest Introductions
6:15 PM - 6:40 PM Structured Networking Session 1
6:40 PM - 7:05 PM Structured Networking Session 2
7:05 PM - 7:30 PM Structured Networking Session 3
7:30 PM - 8:00 PM Closing Remarks & Optional Open Networking
Event Structure
Students will be assigned to a Zoom breakout room for the duration of the event. Following guest introductions, our guests will rotate through three predesignated breakout rooms each for 25 min of networking. Following the closing remarks, trainees will be free to network with any professional of their choice.
We encourage you to follow us on social media (Facebook, LinkedIn and Twitter) for updates and reminders on trainee registration.
Have questions about registration? Email networking@lscds.org or visit our FAQ Page!
Trainee Registration
Note that spots are limited and are available on a first-come, first-serve basis. We will prioritize registrants currently enrolled in a graduate degree (MSc, PhD, other professional degrees) or postdoctoral fellowship at the University of Toronto. Registered individuals who do not show up without notifying our team will be prohibited from attending future LSCDS events.
Event Guests
Dr. Amine Driouchi - Scientist II - Eikon Therapeutics
Amine is currently a Scientist at Eikon Therapeutics where he is developing single-particle-tracking and advanced microscopy assays for drug discovery. Prior to this, Amine was a Postdoctoral Fellow at UChicago and obtained his PhD at UofT working with Dr. Christopher Yip where he worked on super-resolution microscopy of membrane protein biology. In his spare time, Amine likes to play tennis and soccer.
Dr. Mohad Mehrabian - Manager, Technology and Venture Development - CCRM
I am very excited to join LSCDS for this session! As part of the Launch team within Centre for Commercialization of Regenerative Medicine, I lead one of our incubation teams in the immunotherapy space. In my previous role, I led the preclinical activities for the development of a gene regulation therapy for prion diseases at Sangamo therapeutics based in the Bay Area. Prior to that in my postdoctoral studies in Toronto (UofT) and in San Francisco (UCSF), I have explored and identified novel drug targets and developed the relevant in vitro and in vivo screening models for proof of concept studies in the space of neurodegenerative diseases.
Dr. Nabanita Nawar - CEO and Co-Founder - HDAX Therapeutics
Ms. Nabanita Nawar is the CEO and co-founder of HDAX Therapeutics. Nabanita is highly skilled medicinal chemist with proficiency in drug discovery, project design, and strategic thinking. Nabanita’s diverse skillset of 8+ years in drug discovery, leadership, governance, and scientific policy drives the growth of HDAX through her visionary outlook. With 7 high-impact publication, 2 patents, and more than 20 awards, she is a UofT Top Scholar for being the Top 60 most outstanding students of UofT (tri-campus) (2 years in a row), and achieved The Society of Chemical Industry Merit Award, and Canadian Silver Medal from the Chemical Institute of Canada.
Dr. Rylend Mulder - Strategic Operations Manager - Novo Nordisk
Since 2015, Rylend Mulder has been a vocal advocate for advancing STEM trainee and graduate career development opportunities. He received his B.Sc. in Honours Life Sciences from McMaster University and completed his Ph.D. in Microbiology and Immunology at Queen’s University. During his time at Queen’s University, Rylend served as the Graduate Student Ambassador for the Queen’s University Alumni Association and the President of the Department of Biomedical and Molecular Sciences Student Society. In 2015, he launched the second chapter of the non-profit the Science to Business Network (S2BN; www.s2bn.org) at Queen’s University. He currently serves as the volunteer S2BN Executive Director and has led the national expansion from 2 to 10 chapters across five provinces. For the last 3 years, Rylend has worked in the pharmaceutical industry at Novo Nordisk. After starting as a Sales Representative, he is now a Strategic Operations Manager in Medical Affairs.
Dr. Tobias Fuehrmann - Director, Regenerative Medicine - Allarta Life Science
To help develop regenerative therapies, Tobias Führmann works as a Director for Regenerative Medicine at Allarta Life Science. He gained over a decade of interdisciplinary work experience in Germany, the Netherlands, Belgium, Australia, and Canada. His Ph.D. thesis on central nervous system regeneration at the RWTH Aachen sparked his interest in regenerative therapies and has led to a drive to develop curative therapies. Tobias is known for developing cell-based therapies with biomaterials to help alleviate the burdens of degenerative diseases and traumatic injuries.